Published in Mol Cell Biol on March 01, 1994
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J (1996) 2.27
NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol (2003) 2.15
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70
Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol (2009) 1.46
The dorsal-related immunity factor, Dif, is a sequence-specific trans-activator of Drosophila Cecropin gene expression. EMBO J (1995) 1.43
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol (1999) 1.41
Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A (2001) 1.40
Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol (1997) 1.35
The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins. J Virol (1998) 1.31
Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1 A resolution. EMBO J (1997) 1.31
The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol (2002) 1.29
Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res (2000) 1.28
YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. J Virol (1995) 1.26
The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Mol Cell Biol (1999) 1.22
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol (2006) 1.16
Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol Cell Biol (1994) 1.14
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
Functional antagonism between the retinoic acid receptor and the viral transactivator BZLF1 is mediated by protein-protein interactions. Proc Natl Acad Sci U S A (1995) 1.11
An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol (2012) 1.10
A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol (2005) 1.04
Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation. J Virol (2001) 0.98
The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol (2009) 0.98
Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol (2005) 0.97
Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1. J Virol (2005) 0.96
Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha. Nucleic Acids Res (1995) 0.96
Ubinuclein, a novel nuclear protein interacting with cellular and viral transcription factors. J Cell Biol (2000) 0.94
The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog (2012) 0.89
Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication. J Virol (2006) 0.88
Modeling early Epstein-Barr virus infection in Drosophila melanogaster: the BZLF1 protein. Genetics (2005) 0.88
Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J Virol (2000) 0.85
The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol (2010) 0.84
Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA. J Virol (1997) 0.83
Epstein-Barr virus BGLF4 kinase downregulates NF-κB transactivation through phosphorylation of coactivator UXT. J Virol (2012) 0.82
NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1. J Virol (2011) 0.82
Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain. J Virol (2006) 0.80
Epstein-Barr virus BZLF1 protein binds to mitotic chromosomes. J Virol (2005) 0.79
Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway. Blood (2007) 0.79
Interplay of Murine Gammaherpesvirus 68 with NF-kappaB Signaling of the Host. Front Microbiol (2016) 0.78
Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells. J Virol (2014) 0.78
Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. Virol J (2011) 0.76
Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication. J Virol (2015) 0.76
Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci (2016) 0.75
A negative feedback loop of ICER and NF-κB regulates TLR signaling in innate immune responses. Cell Death Differ (2016) 0.75
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell (1986) 15.30
NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell (1989) 11.19
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell (1987) 11.15
The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell (1990) 9.37
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta (1991) 7.70
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J (1986) 6.82
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell (1991) 6.49
Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc Natl Acad Sci U S A (1992) 6.23
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J (1989) 5.93
I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev (1992) 5.67
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev (1989) 5.61
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 5.52
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol (1986) 5.25
Two transcription factors, NF-kappa B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter. Proc Natl Acad Sci U S A (1988) 4.83
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol (1989) 4.25
Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. Science (1992) 4.17
Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J Virol (1984) 4.17
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 4.09
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
A trans-acting factor is responsible for the simian virus 40 enhancer activity in vitro. Nature (1985) 4.01
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell (1991) 3.84
UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol (1989) 3.83
Dorsal, an embryonic polarity gene in Drosophila, is homologous to the vertebrate proto-oncogene, c-rel. Science (1987) 3.74
Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell (1992) 3.55
Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol (1993) 3.51
The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev (1991) 3.24
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J (1989) 3.23
The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J (1989) 3.17
An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol (1990) 3.13
The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J Virol (1989) 3.11
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
The p50 subunit of NF-kappa B associates with the NF-IL6 transcription factor. Proc Natl Acad Sci U S A (1992) 2.93
Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative. Mol Cell Biol (1992) 2.67
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J Virol (1989) 2.43
The inhibitory ankyrin and activator Rel proteins. Curr Opin Genet Dev (1992) 2.39
Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res (1993) 2.38
Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol (1992) 2.26
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene (1991) 2.25
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R. J Virol (1989) 2.20
Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection. Nature (1991) 2.18
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol (1989) 1.86
Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol (1987) 1.84
The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J Virol (1989) 1.79
Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc Natl Acad Sci U S A (1990) 1.79
Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet (1992) 1.79
Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines. J Exp Med (1991) 1.68
Identification of proteins encoded by Epstein-Barr virus trans-activator genes. J Virol (1989) 1.58
The NF-kappa B-binding site mediates phorbol ester-inducible transcription in nonlymphoid cells. Mol Cell Biol (1988) 1.54
Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res (1991) 1.53
Transcriptional activator Tax of HTLV-1 binds to the NF-kappa B precursor p105. Oncogene (1992) 1.49
The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J Virol (1992) 1.47
Identification of a naturally occurring transforming variant of the p65 subunit of NF-kappa B. Science (1992) 1.38
The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol Cell Biol (1992) 1.30
Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus. Virology (1989) 1.19
The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation. J Virol (1992) 1.16
Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci U S A (1993) 1.07
HSV-1-inducible proteins bind to NF-kappa B-like sites in the HSV-1 genome. Virology (1992) 0.96
Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA. Virology (1992) 0.95
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A (1998) 39.20
A whole-genome assembly of Drosophila. Science (2000) 38.48
Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell (1987) 20.61
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell (1992) 9.19
Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA. Cell (1988) 8.00
Gene therapy restores vision in a canine model of childhood blindness. Nat Genet (2001) 7.88
Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol (1993) 6.79
Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell (1991) 6.49
NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol (1999) 5.98
Human CCAAT-binding proteins have heterologous subunits. Cell (1988) 5.81
I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev (1992) 5.67
Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (1995) 5.65
NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science (2000) 5.20
Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene. Mol Cell Biol (1987) 5.05
The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev (1993) 4.93
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol (1987) 4.86
Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 4.85
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 4.55
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene (2006) 4.53
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
Importance of epistasis as the genetic basis of heterosis in an elite rice hybrid. Proc Natl Acad Sci U S A (1997) 4.38
Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol (2001) 4.08
Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 3.82
Complete genomic sequence of Pasteurella multocida, Pm70. Proc Natl Acad Sci U S A (2001) 3.51
Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol (1993) 3.51
Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem (2001) 3.44
Human chromosome 19 and related regions in mouse: conservative and lineage-specific evolution. Science (2001) 3.39
Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes. J Exp Med (1997) 3.32
Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 3.32
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol (1999) 3.30
Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J (1993) 3.28
Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol (2000) 3.23
Detection of preinvasive cancer cells. Nature (2000) 3.20
Regulation of heat shock protein 70 gene expression by c-myc. Nature (1984) 3.18
Giant electrocaloric effect in thin-film PbZr(0.95)Ti(0.05)O3. Science (2006) 3.17
Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol (1995) 3.11
The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci U S A (1992) 3.09
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene (2000) 3.08
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem (2000) 3.00
The p50 subunit of NF-kappa B associates with the NF-IL6 transcription factor. Proc Natl Acad Sci U S A (1992) 2.93
Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity (1995) 2.93
Advances in statistical methods to map quantitative trait loci in outbred populations. Genetics (1997) 2.90
Essential role for ZAP-70 in both positive and negative selection of thymocytes. Nature (1995) 2.88
A yeast and a human CCAAT-binding protein have heterologous subunits that are functionally interchangeable. Cell (1988) 2.84
The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem (1999) 2.79
Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol (1993) 2.77
NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A (1998) 2.61
NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ (2006) 2.59
Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem (1997) 2.55
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. Gastroenterology (2001) 2.46
Transcription control by oncogenes. Cell (1985) 2.45
The association of the distance walked in 6 min with pre-operative peak oxygen consumption and complications 1 month after colorectal resection. Anaesthesia (2013) 2.44
Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res (1993) 2.38
Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg (1999) 2.37
Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. Proc Natl Acad Sci U S A (1994) 2.31
Fluorous mixture synthesis: a fluorous-tagging strategy for the synthesis and separation of mixtures of organic compounds. Science (2001) 2.31
Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol (1998) 2.28
Activation and repression of mammalian gene expression by the c-myc protein. Genes Dev (1987) 2.26
High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart (2003) 2.25
Patterns of cytosine methylation in an elite rice hybrid and its parental lines, detected by a methylation-sensitive amplification polymorphism technique. Mol Gen Genet (1999) 2.23
The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta (2000) 2.20
Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res (2000) 2.18
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res (2001) 2.18
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem (2000) 2.17
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology (1999) 2.16
Molecular analysis of the recF gene of Escherichia coli. Proc Natl Acad Sci U S A (1984) 2.09
The MITE family heartbreaker (Hbr): molecular markers in maize. Proc Natl Acad Sci U S A (2000) 2.08
Brief report: Chlamydia psittaci endocarditis diagnosed by blood culture. N Engl J Med (1992) 2.05
Genome-wide association scan for childhood caries implicates novel genes. J Dent Res (2011) 2.05
Two related helix-loop-helix proteins participate in separate cell-specific complexes that bind the insulin enhancer. Mol Endocrinol (1991) 2.03
Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation (1997) 2.02
Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem (1998) 2.02
Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol (1993) 2.00
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 1.99
Intrinsic fluorescence spectroscopy in turbid media: disentangling effects of scattering and absorption. Appl Opt (2001) 1.98
Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res (1994) 1.98
A novel function of the transforming domain of E1a: repression of AP-1 activity. Cell (1990) 1.97
Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat Struct Biol (1999) 1.95
Molecular characterization of a porcine enteric calicivirus genetically related to Sapporo-like human caliciviruses. J Virol (1999) 1.90
Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation (1998) 1.90
Contrast echocardiography clarifies uninterpretable wall motion in intensive care unit patients. J Am Coll Cardiol (2000) 1.87
Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A (1993) 1.84
Hxt encodes a basic helix-loop-helix transcription factor that regulates trophoblast cell development. Development (1995) 1.82
Chemical and microphysical characterization of ambient aerosols with the aerodyne aerosol mass spectrometer. Mass Spectrom Rev (2007) 1.80
P instability factor: an active maize transposon system associated with the amplification of Tourist-like MITEs and a new superfamily of transposases. Proc Natl Acad Sci U S A (2001) 1.79
NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol (1993) 1.79
A gamma-interferon-induced factor that binds the interferon response sequence of the MHC class I gene, H-2Kb. EMBO J (1989) 1.78
Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation. Mol Cell Biol (2000) 1.78
Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol (1997) 1.78